Liver transplantation for metastasized extragastrointestinal stromal tumor
Standard
Liver transplantation for metastasized extragastrointestinal stromal tumor : a case report and an overview of literature. / Frilling, A; Malago, M; Testa, G; Schleyer, E; Grabellus, F; Kronenberger, R; Broelsch, C E.
in: TRANSPL P, Jahrgang 42, Nr. 9, 11.2010, S. 3843-8.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Liver transplantation for metastasized extragastrointestinal stromal tumor
T2 - a case report and an overview of literature
AU - Frilling, A
AU - Malago, M
AU - Testa, G
AU - Schleyer, E
AU - Grabellus, F
AU - Kronenberger, R
AU - Broelsch, C E
N1 - Crown Copyright © 2010. Published by Elsevier Inc. All rights reserved.
PY - 2010/11
Y1 - 2010/11
N2 - A 63-year-old woman underwent living donor liver transplantation for hepatic metastases of an extragastrointestinal stromal tumor (EGIST) originating from the rectovaginal space. Due to a multifocal extrahepatic tumor recurrence, treatment with imatinib mesylate was started after extensive pharmacokinetic studies to rule out possible interactions with immunosuppressives. We performed several re- resections for EGIST recurrence thereafter. At the last follow-up, 17 years after primary tumor resection and 10 years after living donor liver transplantation, the patient is symptom-free under immunosuppressive and imatinib mesylate treatments with a 2-cm stable recurrent pararectal EGIST. To our knowledge, this is the only report published on a patient who underwent transplantation for hepatic EGIST metastases with a posttransplantation follow-up of 10 years and the first report on living donor liver transplantation for metastasized EGIST. This is the first description of pharmacokinetics of imatinib and its main active metabolite CGP74588 in a liver transplant recipient.
AB - A 63-year-old woman underwent living donor liver transplantation for hepatic metastases of an extragastrointestinal stromal tumor (EGIST) originating from the rectovaginal space. Due to a multifocal extrahepatic tumor recurrence, treatment with imatinib mesylate was started after extensive pharmacokinetic studies to rule out possible interactions with immunosuppressives. We performed several re- resections for EGIST recurrence thereafter. At the last follow-up, 17 years after primary tumor resection and 10 years after living donor liver transplantation, the patient is symptom-free under immunosuppressive and imatinib mesylate treatments with a 2-cm stable recurrent pararectal EGIST. To our knowledge, this is the only report published on a patient who underwent transplantation for hepatic EGIST metastases with a posttransplantation follow-up of 10 years and the first report on living donor liver transplantation for metastasized EGIST. This is the first description of pharmacokinetics of imatinib and its main active metabolite CGP74588 in a liver transplant recipient.
KW - Antineoplastic Agents
KW - Benzamides
KW - Female
KW - Gastrointestinal Stromal Tumors
KW - Humans
KW - Imatinib Mesylate
KW - Immunosuppressive Agents
KW - Liver Neoplasms
KW - Liver Transplantation
KW - Living Donors
KW - Middle Aged
KW - Neoplasm Recurrence, Local
KW - Piperazines
KW - Pyrimidines
KW - Rectal Neoplasms
KW - Time Factors
KW - Treatment Outcome
KW - Vaginal Neoplasms
KW - Case Reports
KW - Journal Article
KW - Review
U2 - 10.1016/j.transproceed.2010.06.016
DO - 10.1016/j.transproceed.2010.06.016
M3 - SCORING: Review article
C2 - 21094867
VL - 42
SP - 3843
EP - 3848
JO - TRANSPL P
JF - TRANSPL P
SN - 0041-1345
IS - 9
ER -